Innovating.works Conecta tu I+D

Showing 1 to 20 of 80 results

VICT3R: Developing and implementing VIrtual Control groups To reducE animal use in toxicology Research VICT3R, a public-private partnership running under the European Innovative Health Initiative, aims to significantly reduce the number of ani...
2024-07-26 - 2028-02-29 | Financiado

LIVERAIM: A Biomarker Based Platform for Early Diagnosis of Chronic Liver Disease to Enable Personalized Thera... BOEHRINGER INGELHEIM INTERNATIONALGMBH participó en un HORIZON EUROPE: HORIZON-JU-IHI-2022-03-single-stage Liver cirrhosis and liver cancer are common and responsible for high morbidity, impaired quality of life, major costs for healthcare systems...
2023-11-27 - 2030-02-28 | Financiado

RealHOPE: Real World Handling of Protein Drugs Exploration Evaluation and Education BOEHRINGER INGELHEIM INTERNATIONALGMBH participó en un H2020: H2020-JTI-IMI2-2020-20-two-stage RealHOPE will create an understanding of the real-life handling of protein drugs in hospital pharmacy, clinics and in the hands of patients...
2021-07-05 - 2025-06-30 | Financiado

PRISM 2: Psychiatric Ratings using Intermediate Stratified Markers 2 BOEHRINGER INGELHEIM INTERNATIONALGMBH participó en un H2020: H2020-JTI-IMI2-2020-22-single-stage The current nosology of neuropsychiatric disorders provides a pragmatic approach to diagnosis and treatment choice but lacks reference to qu...
2021-05-19 - 2024-11-30 | Financiado

BIGPICTURE: Central Repository for Digital Pathology BOEHRINGER INGELHEIM INTERNATIONALGMBH participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage BIGPICTURE, a pathology-led consortium, has the vision to become the catalyst in digital transformation in Pathology. Our mission is to crea...
2020-11-26 - 2027-01-31 | Financiado

SISAQOL-IMI: Establishing international standards in the analysis of patient reported outcomes and health related... BOEHRINGER INGELHEIM INTERNATIONALGMBH participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage Measuring and quantifying how a patient feels or functions during treatment is an important endpoint in cancer clinical trials. It is genera...
2020-11-09 - 2024-12-31 | Financiado

CARE: Corona Accelerated R D in Europe BOEHRINGER INGELHEIM INTERNATIONALGMBH participó en un H2020: H2020-JTI-IMI2-2020-21-single-stage The Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) pandemic has emerged as the largest global health threat to humanity in thi...
2020-08-07 - 2025-03-31 | Financiado

SOPHIA: Stratification of Obesity Phenotypes to Optimize Future Therapy BOEHRINGER INGELHEIM INTERNATIONALGMBH participó en un H2020: H2020-JTI-IMI2-2019-17-two-stage SOPHIA will optimise the future treatment of obesity. The challenge is that clinicians, payers and patients view obesity as a failure of sel...
2020-05-26 - 2025-05-31 | Financiado

EUbOPEN: EUbOPEN Enabling and Unlocking biology in the OPEN BOEHRINGER INGELHEIM INTERNATIONALGMBH participó en un H2020: H2020-JTI-IMI2-2019-17-two-stage The EUbOPEN partnership of excellence will aim to generate the largest freely available set of high-quality chemical inhibitors for human pr...
2020-05-11 - 2025-04-30 | Financiado

PharmaLedger: PharmaLedger BOEHRINGER INGELHEIM INTERNATIONALGMBH participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage The PharmaLedger project will create a blockchain-based framework for the efficient digitization of the healthcare industry. The goal of the...
2019-12-16 - 2022-12-31 | Financiado

imSAVAR: Immune Safety Avatar nonclinical mimicking of the immune system effects of immunomodulatory therapi... BOEHRINGER INGELHEIM INTERNATIONALGMBH participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage The vision of Immune Safety Avatar (imSAVAR) is to develop a platform for integrated nonclinical assessments of immunomodulatory therapy saf...
2019-11-18 - 2025-11-30 | Financiado

Trials@Home: Trials@Home Center of Excellence Remote Decentralised Clinical Trials BOEHRINGER INGELHEIM INTERNATIONALGMBH participó en un H2020: H2020-JTI-IMI2-2018-14-two-stage Clinical trials increase in size, complexity and costs. This is fuelled with the need to demonstrate effects in more complex therapeutic are...
2019-08-07 - 2025-11-30 | Financiado

MELLODDY: MachinE Learning Ledger Orchestration for Drug DiscoverY BOEHRINGER INGELHEIM INTERNATIONALGMBH participó en un H2020: H2020-JTI-IMI2-2018-14-two-stage MELLODDY will demonstrate how the pharmaceutical industry can better leverage its data assets to virtualize the Drug Discovery (DD) process...
2019-05-22 - 2022-05-31 | Financiado

BIOMAP: Biomarkers in Atopic Dermatitis and Psoriasis BOEHRINGER INGELHEIM INTERNATIONALGMBH participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage Our objective is to provide a taxonomic and predictive systems medicine model of Atopic Dermatitis and Psoriasis based on clinical and molec...
2019-02-27 - 2025-03-31 | Financiado

FAIRplus: FAIRplus BOEHRINGER INGELHEIM INTERNATIONALGMBH participó en un H2020: H2020-JTI-IMI2-2017-12-two-stage Wide sharing of knowledge and data drives the progression of science. Shared data allows other researchers to reproduce findings and benchma...
2018-12-18 - 2022-12-31 | Financiado

EHDEN: European Health Data and Evidence Network BOEHRINGER INGELHEIM INTERNATIONALGMBH participó en un H2020: H2020-JTI-IMI2-2017-12-two-stage Europe is generating huge amounts of patient-level information contained in Electronic Health Record (EHR) systems and other types of health...
2018-11-22 - 2024-10-31 | Financiado

ReSOLUTE: Research empowerment on solute carriers ReSOLUTE BOEHRINGER INGELHEIM INTERNATIONALGMBH participó en un H2020: H2020-JTI-IMI2-2016-10-two-stage The Research empowerment on solute carriers (ReSOLUTE) proposal aims at inducing a decisive acceleration in the intensity of SLC research wo...
2018-06-22 - 2023-12-31 | Financiado

LITMUS: Liver Investigation Testing Marker Utility in Steatohepatitis BOEHRINGER INGELHEIM INTERNATIONALGMBH participó en un H2020: H2020-JTI-IMI2-2016-09-two-stage Strongly associated with the epidemics of obesity and type 2 diabetes that are testing healthcare systems worldwide, Non-Alcoholic Fatty Liv...
2017-10-09 - 2024-02-29 | Financiado

eTRANSAFE: Enhacing TRANslational SAFEty Assessment through Integrative Knowledge Management BOEHRINGER INGELHEIM INTERNATIONALGMBH participó en un H2020: H2020-JTI-IMI2-2016-09-two-stage Drug safety assessment is a knowledge-intensive process that demands advancement in data handling methods and tools for facilitating data sh...
2017-09-12 - 2023-02-28 | Financiado

EQIPD: European Quality In Preclinical Data BOEHRINGER INGELHEIM INTERNATIONALGMBH participó en un H2020: H2020-JTI-IMI2-2016-09-two-stage Pharmaceutical industry, as well as basic science, depend on robust data and scientific rigor as key drivers for decision making, patent str...
2017-08-18 - 2021-09-30 | Financiado

BII GMBH